Global CRISPR Gene Editing Therapies Market — Size, Share & Forecast 2026-2035

CRISPR Gene Editing Therapies Market size was valued at $4.71 Bn in 2026 and it will grow $18.96 Bn at a CAGR of 12.9% by 2026 to 2035

The CRISPR gene editing therapies market is projected to grow from USD 4.71 billion in 2026 to USD 18.96 billion by 2035 at a 12.9% CAGR (2025 base of USD 3.84 billion).

Growth follows the first commercial CRISPR therapy approvals and pipeline expansion.

Market Snapshot Revenue, 2026: 4.71 Billion Forecast, 2035: 18.96 Billion CAGR, 2026-2035: 12.9% Report Coverage: Global Key Companies CRISPR Therapeutics AG Vertex Pharmaceuticals Incorporated Intellia Therapeutics Inc.

Veena JagtapJune 23, 2026 · 2 min read · Austin, TX, USA

Article Overview

The CRISPR gene editing therapies market is projected to grow from USD 4.71 billion in 2026 to USD 18.96 billion by 2035 at a 12.9% CAGR (2025 base of USD 3.84 billion). Growth follows the first commercial CRISPR therapy approvals and pipeline expansion.

Market Snapshot

Revenue, 2026: 4.71 Billion
Forecast, 2035: 18.96 Billion
CAGR, 2026-2035: 12.9%
Report Coverage: Global

Key Companies

CRISPR Therapeutics AG
Vertex Pharmaceuticals Incorporated
Intellia Therapeutics Inc.
Editas Medicine Inc.
Beam Therapeutics Inc.
Prime Medicine Inc.
Caribou Biosciences Inc.
Allogene Therapeutics Inc.
Verve Therapeutics Inc.
Precision BioSciences Inc.
Others

About Healthcare Foresights

Healthcare Foresights provides market research and consulting across the healthcare and life sciences industry, combining industry research, analytical expertise and technology-enabled solutions to help companies, investors and decision-makers identify opportunities and drive growth. For the full report, customization or a sample, contact our team.

Explore More Healthcare Insights

Explore research perspectives, market developments and healthcare industry analysis from Healthcare Foresights.

View All Insights →